Retatrutide Goes the Distance: The Full Phase 3 Diabetes Data Is Here
DR
Dr. Anna Chereshnevskyi · General Practitioner ·
Retatrutide has been one of the most talked-about drugs in the weight loss and diabetes world for a couple of years, mostly on the strength of early studies. At the American Diabetes Association meeting in June 2026, Eli Lilly finally put its first full Phase 3 results on the table, and they were published the same week in the medical journal The Lancet. The trial was called TRANSCEND-T2D-1, and it tested the drug in people with type 2 diabetes.
The short version: it worked, and it worked at every dose. Here is a plain-language look at what the study found and why people are paying attention.
What makes retatrutide different
Retatrutide is what scientists call a triple agonist. That means it works on three different body signals at once. The first two, called GLP-1 and GIP, are the same targets used by drugs like tirzepatide (sold as Mounjaro and Zepbound). Retatrutide adds a third, called glucagon, which helps the body burn energy. Stacking three signals together is the reason many researchers expected bigger results than the current drugs, which hit one or two.
The numbers, in plain terms
The trial included 537 people whose type 2 diabetes was not well controlled. They were split into four groups: three got retatrutide at different strengths (4, 9, or 12 milligrams), and one got a placebo, which is a dummy shot with no medicine. The study ran for 40 weeks.
For blood sugar, doctors track a number called A1c, which shows your average blood sugar over the past few months. Lower is better. The top dose of retatrutide brought A1c down by about 1.9 percentage points, compared with about 0.8 for the placebo. By the end, roughly 9 in 10 people on the drug had pushed their A1c below 7 percent, which is the common target for good control.
Weight loss was the headline, though. At the highest dose, people lost about 17 percent of their body weight, which works out to roughly 37 pounds for many of them. And the weight was still dropping at week 40, with no sign of leveling off. That last detail matters: it suggests people may have kept losing weight if the study had run longer.
There were extra benefits too. The drug lowered blood fats called triglycerides, nudged down blood pressure, and trimmed waist size. For people with diabetes, who often carry heart risks as well, those side effects are the good kind.
How it fits the bigger picture
This result did not come out alone. It landed during a packed week of diabetes and weight loss news, which we walked through in our roundup of the five big ADA 2026 drug results. The theme across all of them is the same: the newest drugs are pushing weight loss numbers higher and adding heart and metabolic benefits on top.
Retatrutide sits at the strong end of that trend. Where companies like Pfizer are competing on convenience, such as a once-a-month shot, retatrutide is competing on raw results. Both matter to different people. Someone who needs to lose a large amount of weight may care most about the size of the result, while someone who just wants an easier routine may care more about how often they have to take it.
A few honest caveats
This was a diabetes trial, not an obesity trial. A separate, larger study in people with obesity (called TRIUMPH-1) is still expected later in 2026, and that one will tell us more about weight loss in people without diabetes. Retatrutide is also not approved or on pharmacy shelves yet. Strong Phase 3 data is a big step, but a drug still has to clear review before doctors can prescribe it.
Side effects are worth watching as well. Like other drugs in this family, retatrutide can cause nausea and other stomach problems, and the higher doses tend to bring more of them. The full safety picture will keep coming into focus as more studies report.
Still, for a drug that built its reputation on early promise, this was the moment it had to prove itself in a large, careful study. It did. Retatrutide now looks like one of the most powerful options coming down the line for people living with type 2 diabetes and excess weight.
DR
Written by
Dr. Anna Chereshnevskyi
General Practitioner
Dr. Chereshnevskyi is a general practitioner who graduated from Lviv National Medical University and currently practices at a state hospital in Ankara, Turkey. She specialises in primary care and follows the clinical literature on peptide therapies, metabolic health, and longevity research. She contributes to Peptide.pub as a medical reviewer and blog author, translating complex research into plain, evidence-based language.
About Peptide.pub →